A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

drug protocol number
MO40628
drug sponsor
Roche
drug study
Trastuzumab & Pertuzumab
drug trial site
KFSH & KFMC
drug status
Completed
drug phase